The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy Virtual 2020 | A CAR-T round-up with Arnon Nagler
CAR T-cell therapy is revolutionizing the treatment of hematological malignancy. Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses CAR-T approaches to the treatment of acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and multiple myeloma,. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
